Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel

References

• RobertCSoriaJCSpatzACutaneous side-effects of kinase inhibitors and blocking antibodiesLancet Oncol20056749150015992698
   PubMed Web of Science ®Google Scholar
• SegaertSChiritescuGLemmensLDumonKVan CutsemETejparSSkin toxicities of targeted therapiesEur J Cancer200945Suppl 129530819775626
   PubMedGoogle Scholar
• Perez-SolerRDelordJPHalpernAHER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forumOncologist200510534535615851793
   PubMed Web of Science ®Google Scholar
• LacoutureMELaiSEThe PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndromeBr J Dermatol2006155485285416965448
   PubMed Web of Science ®Google Scholar
• AgeroALDuszaSWBenvenuto-AndradeCBusamKJMyskowskiPHalpernACDermatologic side effects associated with the epidermal growth factor receptor inhibitorsJ Am Acad Dermatol200655465767017010747
   PubMed Web of Science ®Google Scholar
• LynchTJJrKimESEabyBGareyJWestDPLacoutureMEEpidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical managementOncologist200712561062117522250
   PubMed Web of Science ®Google Scholar
• CampbellJLaneCDeveloping a skin-care protocol in radiotherapyProf Nurse19961221051089128655
   PubMedGoogle Scholar
• BolderstonALloydNSWongRKHoldenLRobb-BlendermanLSupportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guidelineSupport Care Cancer200614880281716758176
   PubMed Web of Science ®Google Scholar
• PeuvrelLBachmeyerCReguiaiZSemiology of skin toxicity associated with epidermal growth factor receptor inhibitorsSupport Care Cancer210220590992122361824
   PubMedGoogle Scholar
• McQuestionMEvidence-based skin care management in radiation therapySemin Oncol Nurs200622316317316893745
   PubMedGoogle Scholar
• ReguiaiZBachetJBachmeyerCManagement of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithmSupport Care Cancer20122071395140422539049
   PubMed Web of Science ®Google Scholar
• BernierJBonnerJVermorkenJConsensus guidelines for the management of radiation dermatitis and coexisting acne like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neckAnn Oncol200819114214917785763
   PubMed Web of Science ®Google Scholar
• FluhrJMitevaMPrimaveraGZiemerMElsnerPBerardescaEFunctional assessment of a skin care system in patients on chemotherapySkin Pharmacol Physiol200720525325917587889
   PubMed Web of Science ®Google Scholar
• JatoiANguyenPLDo patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapyOncologist200813111201120418988655
   PubMed Web of Science ®Google Scholar
• HaleyACalahanCGandhiMWestDRademakerALacoutureMSkin care management in cancer patients: an evaluation of quality of life and tolerabilitySupport Care Cancer201119454555420336328
   PubMed Web of Science ®Google Scholar
• WackerBNagraniTWeinbergJWittKClarkGCagnoniPCorrelation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studiesClin Cancer Res2007131339123921
   Web of Science ®Google Scholar
• WolfMSwaislandHAverbuchSDevelopment of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacyClin Cancer Res200410144607461315269131
   PubMed Web of Science ®Google Scholar
• MelowskyBBurkesRRaysonDAlkindorTShearNLacoutureMEManagement of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendationsCurr Oncol20091611726
   Web of Science ®Google Scholar
• BurtnessBAnadkatMBastiSNCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerJ Nat Compr Canc Netw20097Suppl 1S5S21
   PubMed Web of Science ®Google Scholar
• KumarSJuresicEBartonMShafiqJManagement of skin toxicity during radiation therapy: a review of the evidenceJ Med Imaging Radiat Oncol201054326427920598015
   PubMed Web of Science ®Google Scholar
• NoushinHHaleyNSusanBChemotherapeutic agents and the skin: an updateJ Am Acad Dermatol20085854557018342708
   PubMed Web of Science ®Google Scholar
• Maddocks-JenningsWWilkinsonJMShillingtonDNovel approaches to radiotherapy-induced skin reactions: A literature reviewComplement Ther Clin Pract200511422423116290892
   PubMedGoogle Scholar
• JatoiAGreenEMRowlandKMJrSargentDJAlbertsSRClinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147Oncology200977212012319622902
   PubMed Web of Science ®Google Scholar
• SegaertSVan CutsemEClinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnn Oncol20051691425143316012181
   PubMed Web of Science ®Google Scholar
• RoeEGarcia MuretMPMarcuelloECapdevilaJPallaresCAlomarADescription and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patientsJ Am Acad Dermatol200655342943716908348
   PubMed Web of Science ®Google Scholar
• OuwerkerkJBoers-DoetsCBest practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancerEur J Oncol Nurs201014433734920580896
   PubMed Web of Science ®Google Scholar
• MooreSManaging treatment side effects in advanced breast cancerSemin Oncol Nurs2007234 Suppl 2S23S3018054679
   PubMedGoogle Scholar
• Galimont-CollenAFVosLELavrijsenAPOuwerkerkJGelderblomHClassification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitorsEur J Cancer200743584585117289377
   PubMed Web of Science ®Google Scholar
• HuJCSadeghiPPinter-BrownLCYasharSChiuMWCutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and managementJ Am Acad Dermatol200756231732617141360
   PubMed Web of Science ®Google Scholar
• WohlrabJLuftnerDJohneACamaraODominikSRunnebaumIThe advantage of a proactive, barrier-protective, supportive skin care in patients with brest cancer on chemotherapyOncology201134662
   Google Scholar
• El-AbaseriTHansenLEGFR activation and ultraviolet light-induced skin carcinogenesisJ Biomed Biotechnol2007200739793917541473
   PubMedGoogle Scholar
• JacotWBessisDJordaEYchouMFabbroMPujolJAcniform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBr J Dermatol2004151123824115270903
   PubMed Web of Science ®Google Scholar
• LuuM LSPatelJGuitartJLacoutureMEPhotosensitive rash due to the epidermal growth factor receptor inhibitor erlotinibPhotodermatol Photoimmunol Photomed2007231424517254038
   PubMed Web of Science ®Google Scholar
• FunkeAKulp-ShortenCCallenJSubacute cutaneous lupus erythematosus exacerbated or induced by chemotherapyArch Dermatol2010146101113111620956642
   PubMedGoogle Scholar
• Perez-SolerRSaltzLCutaneous adverse events with HER1/EGFR-targeted agents: is there a silver lining?J Clin Oncol200523225235524616051966
   PubMed Web of Science ®Google Scholar
• RigopoulosDLariosGGregoriouSAlevizosAAcute and chronic paronychiaAm Fam Phys2008773339346
   PubMed Web of Science ®Google Scholar
• RongiolettiFBallestreroABoglioloFReboraANecrotizing eccrine squamous syringometaplasia presenting as acral erythemaJ Cutan Pathol19911864534561774355
   PubMed Web of Science ®Google Scholar
• Wasif SaifMAymenAIdentifying and treating fluoropyridimine-associated hand and foot syndrome in white and non-white patientsJ Support Oncol20075733734317708124
   PubMedGoogle Scholar
• ScheithauerWBlumJComing to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabineOncology (Williston Park)20041891161116815471200
   PubMed Web of Science ®Google Scholar
• TitecaGPootFCassartDImpact of cosmetic care on quality of life in breast cancer patients during chemotherapy and radiologyJ Eur Acad Dermatol Venereol200721677177617567306
   PubMed Web of Science ®Google Scholar
• HirshVManaging treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancerCurr Oncol201118312613821655159
   PubMed Web of Science ®Google Scholar
• WilliamsSSchreierAThe effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancerOncol Nurs Forum2004311E16E2314722602
   PubMed Web of Science ®Google Scholar
• AndersonMJohnsonJRestoration of body image and self-esteem for women after cancer treatment: a rehabilitative surveyCancer Pract1994253453497697072
   PubMedGoogle Scholar
• FawzyNSecherLEvansSGiulianoAThe Positive Appearance Center: an innovative concept in comprehensive psychosocial cancer careCancer Pract1995342332387620488
   PubMedGoogle Scholar
• BooneSLRademakerALiuDPfeifferCMauroDJLacoutureMEImpact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey resultsOncology2007723–415215918160805
   PubMed Web of Science ®Google Scholar
• WolfRWolfDTüzünBTüzünYSoaps, shampoos, detergentsClin Dermatol200119439339711535379
   PubMed Web of Science ®Google Scholar
• LacoutureMEMechanisms of cutaneous toxicities to EGFR inhibitorsNat Rev Cancer200661080381216990857
   PubMed Web of Science ®Google Scholar
• ThunePThe effects of detergents on hydration and skin surface lipidsClin Dermatol199614129338901396
   PubMed Web of Science ®Google Scholar